Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
Conditions: Breast Cancer; Breast Cancer Female; HER2-positive Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III Interventions: Drug: Docetaxel; Drug: Herceptin; Drug: FEC; Drug: Tamoxifen; Drug: Letrozole; Drug: LHRH agonist Sponsor: University of Chicago Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Nigeria Health | Research | Tamoxifen | Taxotere | Women